K. Campbell, S. Brosseau, L. Reviron-rabec, E. Bergot, E. Lechapt et al., Malignant pleural mesothelioma: 2013 state of the art]. Bull Cancer (Paris), pp.1283-93, 2013.

L. Stang, N. Belot, A. , G. Soit-ilg, A. Rolland et al., Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005, International Journal of Cancer, vol.26, issue.1, pp.232-240, 1980.
DOI : 10.1002/ijc.24711

URL : https://hal.archives-ouvertes.fr/hal-00698003

. Inca, Mésothéliome pleural malin-Guide du Parcours de Soins. wwwhas-santefr wwwe-cancerfr [serial on the Internet, 2013.

R. Spirtas, E. Heineman, L. Bernstein, G. Beebe, R. Keehn et al., Malignant mesothelioma: attributable risk of asbestos exposure., Occupational and Environmental Medicine, vol.51, issue.12, pp.804-815, 1994.
DOI : 10.1136/oem.51.12.804

A. Cavazza, L. Travis, W. Travis, J. Wolfe, M. Foo et al., Post-irradiation malignant mesothelioma. Cancer, pp.1379-85, 1996.
DOI : 10.1002/(sici)1097-0142(19960401)77:7<1379::aid-cncr24>3.0.co;2-y

W. Travis, E. Brambilla, H. Müller-hermelink, and C. Harris, Tumours of the pleura. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, 2015.

J. Shia, J. Qin, R. Erlandson, R. King, P. Illei et al., Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases, Virchows Archiv, vol.52, issue.5, 2005.
DOI : 10.1007/s00428-005-0035-y

J. Leigh, P. Davidson, L. Hendrie, and D. Berry, Malignant mesothelioma in Australia, Am J Ind Med, 1945.

M. Carbone, B. Ly, R. Dodson, I. Pagano, P. Morris et al., Malignant mesothelioma: Facts, Myths, and Hypotheses, Journal of Cellular Physiology, vol.57, issue.1, pp.44-58
DOI : 10.1002/jcp.22724

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143206

S. Moolgavkar, R. Meza, and J. Turim, Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control CCC, pp.935-979, 2009.

T. Burki, Health experts concerned over India's asbestos industry, The Lancet, vol.375, issue.9715, pp.626-633, 2010.
DOI : 10.1016/S0140-6736(10)60251-6

P. Godard, B. Housset, B. Crestani, C. Marquette, A. Scherpereel et al., Recommandations de la Société Française de Pneumologie de Langue Française sur le mésothéliome pleural-Conférence d'experts, 2006.

P. Grosclaude, N. Bossard, L. Remontet, A. Belot, P. Arveux et al., Survie des patients atteints de cancer en France, 2007.
DOI : 10.1007/978-2-287-39310-5

URL : https://hal.archives-ouvertes.fr/hal-00434568

J. Edwards, K. Abrams, J. Leverment, T. Spyt, D. Waller et al., Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems, Thorax, vol.55, issue.9, 2000.
DOI : 10.1136/thorax.55.9.731

. Inca, Amiante et mésothéliome pleural malin Institut National du Cancer. [Prévention], 2012.

J. Wagner, C. Sleggs, and P. Marchand, Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province, Occupational and Environmental Medicine, vol.17, issue.4, pp.260-71, 1960.
DOI : 10.1136/oem.17.4.260

J. Hodgson and A. Darnton, The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure, The Annals of Occupational Hygiene, vol.44, issue.8, pp.565-601, 2000.
DOI : 10.1016/S0003-4878(00)00045-4

D. Kamp, Asbestos-induced lung diseases: an update, Translational Research, vol.153, issue.4, pp.143-52, 2009.
DOI : 10.1016/j.trsl.2009.01.004

A. Lee, D. Raz, B. He, and D. Jablons, Update on the molecular biology of malignant mesothelioma. Cancer, 2007.

N. Heintz, Y. Janssen-heininger, and B. Mossman, Asbestos, Lung Cancers, and Mesotheliomas, American Journal of Respiratory Cell and Molecular Biology, vol.42, issue.2, pp.133-142, 2010.
DOI : 10.1165/rcmb.2009-0206TR

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822975

M. Carbone and H. Pass, Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. Feb, vol.1, issue.2, pp.169-71, 2006.

A. Musk, N. Olsen, H. Alfonso, A. Reid, R. Mina et al., Predicting survival in malignant mesothelioma, European Respiratory Journal, vol.38, issue.6, pp.1420-1424, 2011.
DOI : 10.1183/09031936.00000811

K. Kadota, K. Suzuki, C. Colovos, C. Sima, V. Rusch et al., A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma, Modern Pathology, vol.15, issue.2, pp.260-71, 2012.
DOI : 10.1158/0008-5472.CAN-09-3993

A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, H. Clayson et al., Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, European Respiratory Journal, vol.35, issue.3, pp.23-45, 2010.
DOI : 10.1183/09031936.00063109

F. Galateau-sallé, G. Soit-ilg, A. , L. Stang, N. Brochard et al., M??soth??liome??: les dispositifs en place en France ????le r??seau m??soth??liome???? 1998???2013, Annales de Pathologie, vol.34, issue.1, pp.51-63, 1998.
DOI : 10.1016/j.annpat.2014.01.009

A. Husain, T. Colby, N. Ordonez, T. Krausz, R. Attanoos et al., Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Archives of Pathology & Laboratory Medicine, vol.137, issue.5, pp.647-67, 2013.
DOI : 10.5858/arpa.2012-0214-OA

L. Br?i?, M. Jakopovi?, I. Br?i?, V. Klari?, M. Milo?evi? et al., Reproducibility of histological subtyping of malignant pleural mesothelioma, Virchows Archiv, vol.23, issue.6, pp.679-85, 2014.
DOI : 10.1007/s00428-014-1664-9

F. Galateau-sallé, J. Vignaud, L. Burke, A. Gibbs, E. Brambilla et al., Well-differentiated Papillary Mesothelioma of the Pleura, The American Journal of Surgical Pathology, vol.28, issue.4, pp.534-574, 2004.
DOI : 10.1097/00000478-200404000-00013

H. Yaziji, H. Battifora, T. Barry, H. Hwang, C. Bacchi et al., Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity, Modern Pathology, vol.19, issue.4, pp.514-537, 2006.
DOI : 10.1038/modpathol.3800534

B. Addis and H. Roche, Problems in mesothelioma diagnosis, Histopathology, vol.48, issue.1, pp.55-68, 2009.
DOI : 10.1111/j.1365-2559.2008.03178.x

S. Klebe, N. Brownlee, A. Mahar, J. Burchette, T. Sporn et al., Sarcomatoid mesothelioma: a clinical???pathologic correlation of 326 cases, Modern Pathology, vol.22, issue.3, pp.470-479, 2010.
DOI : 10.1046/j.1365-2559.41.s2.41.x

A. Churg, T. Colby, P. Cagle, J. Corson, A. Gibbs et al., The Separation of Benign and Malignant Mesothelial Proliferations, Archives of Pathology & Laboratory Medicine, vol.136, issue.10, pp.1183-200, 2000.
DOI : 10.5858/arpa.2012-0112-RA

A. Abutaily, B. Addis, and W. Roche, Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies, Journal of Clinical Pathology, vol.55, issue.9, pp.662-670, 2002.
DOI : 10.1136/jcp.55.9.662

R. Carella, G. Deleonardi, D. Errico, A. Salerno, A. Egarter-vigl et al., Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma, The American Journal of Surgical Pathology, vol.25, issue.1, pp.43-50, 2001.
DOI : 10.1097/00000478-200101000-00004

E. Duhig, L. Kalpakos, I. Yang, and B. Clarke, Mesothelial markers in high-grade breast carcinoma, Histopathology, vol.98, issue.5, pp.957-64, 2011.
DOI : 10.1111/j.1365-2559.2011.04036.x

N. Ordóñez, Application of mesothelin immunostaining in tumor diagnosis, Am J Surg Pathol, 2003.

Y. Takeshima, V. Amatya, K. Kushitani, and K. Inai, A Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases, American Journal of Clinical Pathology, vol.130, issue.5, 2008.
DOI : 10.1309/AJCPHSUJ15NEYMIP

A. Churg, P. Cagle, T. Colby, J. Corson, A. Gibbs et al., The Fake Fat Phenomenon in Organizing Pleuritis, The American Journal of Surgical Pathology, vol.35, issue.12, 2011.
DOI : 10.1097/PAS.0b013e31822a2481

G. Ugurluer, K. Chang, M. Gamez, A. Arnett, R. Jayakrishnan et al., A Comprehensive Genome-Based Mutational Analysis by Next Generation Sequencing Technology in Patients With Malignant Pleural and Peritoneal Mesothelioma, International Journal of Radiation Oncology*Biology*Physics, vol.93, issue.3
DOI : 10.1016/j.ijrobp.2015.07.444

M. Hylebos, V. Camp, G. Van-meerbeeck, J. Op-de-beeck, and K. , The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing, Journal of Thoracic Oncology, vol.11, issue.10, 2016.
DOI : 10.1016/j.jtho.2016.05.020

A. Borczuk, P. J. Taub, R. Levy, B. Nahum, O. Chen et al., Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration, Cancer Biology & Therapy, vol.50, issue.3, pp.328-363, 2016.
DOI : 10.1038/nrc1299

B. Rihn, S. Mohr, S. Mcdowell, S. Binet, J. Loubinoux et al., Differential gene expression in mesothelioma, FEBS Letters, vol.49, issue.2-3, pp.2-395, 2000.
DOI : 10.1016/S0014-5793(00)01913-X

R. Bueno, E. Stawiski, L. Goldstein, S. Durinck, D. Rienzo et al., Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nature Genetics, vol.8, issue.4, pp.407-423
DOI : 10.1101/gr.133744.111

M. Bott, M. Brevet, B. Taylor, S. Shimizu, T. Ito et al., The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nature Genetics, vol.3, issue.7, 2011.
DOI : 10.1186/gb-2007-8-11-r232

M. Ladanyi, M. Zauderer, L. Krug, T. Ito, R. Mcmillan et al., New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment, Clinical Cancer Research, vol.18, issue.17, pp.4485-90, 2012.
DOI : 10.1158/1078-0432.CCR-11-2375

Y. Yoshikawa, A. Sato, T. Tsujimura, M. Emi, T. Morinaga et al., Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma, Cancer Science, vol.29, issue.5, pp.868-74
DOI : 10.1111/j.1349-7006.2012.02223.x

L. Righi, E. Duregon, S. Vatrano, S. Izzo, J. Giorcelli et al., BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study, Journal of Thoracic Oncology, vol.11, issue.11, 2016.
DOI : 10.1016/j.jtho.2016.06.020

A. Churg, B. Sheffield, and F. Galateau-salle, New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?, Archives of Pathology & Laboratory Medicine, vol.140, issue.4, pp.318-339
DOI : 10.5858/arpa.2015-0240-SA

H. Hwang, S. Pyott, S. Rodriguez, A. Cindric, A. Carr et al., BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas, The American Journal of Surgical Pathology, vol.40, issue.5, 2016.
DOI : 10.1097/PAS.0000000000000616

C. Ribeiro, S. Campelos, C. Moura, J. Machado, A. Justino et al., Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation, Annals of Oncology, vol.24, issue.8, pp.2147-50, 2013.
DOI : 10.1093/annonc/mdt135

J. Testa, M. Cheung, P. J. Below, J. Tan, Y. Sementino et al., Germline BAP1 mutations predispose to malignant mesothelioma, Nature Genetics, vol.55, issue.10, pp.1022-1027, 2011.
DOI : 10.1038/onc.2009.455

M. Tetzlaff, C. Torres-cabala, P. Pattanaprichakul, R. Rapini, V. Prieto et al., Emerging clinical applications of selected biomarkers in melanoma, Clin Cosmet Investig Dermatol, vol.8, pp.35-46, 2015.

M. Carbone, L. Ferris, F. Baumann, A. Napolitano, C. Lum et al., BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs, Journal of Translational Medicine, vol.10, issue.1, p.179, 2012.
DOI : 10.1002/cncr.10159

P. Illei, V. Rusch, M. Zakowski, and M. Ladanyi, Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas, Clin Cancer Res Off J Am Assoc Cancer Res, vol.9, issue.6, pp.2108-2121, 2003.

L. Wong, J. Zhou, D. Anderson, and R. Kratzke, Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer Amst Neth, pp.131-137, 2002.

M. Ladanyi, Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer Amst Neth, 2005.

H. Hwang, B. Sheffield, S. Rodriguez, K. Thompson, C. Tse et al., Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens, The American Journal of Surgical Pathology, vol.40, issue.1, pp.120-126, 2016.
DOI : 10.1097/PAS.0000000000000529

H. Hwang, C. Tse, S. Rodriguez, A. Gown, and A. Churg, p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma, The American Journal of Surgical Pathology, vol.38, issue.5, pp.681-689, 2014.
DOI : 10.1097/PAS.0000000000000176

D. Wu, K. Hiroshima, S. Matsumoto, K. Nabeshima, T. Yusa et al., Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis, American Journal of Clinical Pathology, vol.139, issue.1, 2013.
DOI : 10.1309/AJCPT94JVWIHBKRD

S. Dacic, H. Kothmaier, S. Land, Y. Shuai, I. Halbwedl et al., Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas, Virchows Archiv, vol.16, issue.6, pp.627-662, 2008.
DOI : 10.1007/s00428-008-0689-3

F. Galateau-salle, A. Churg, V. Roggli, and W. Travis, World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the, 2004.

T. Soussi, K. Dehouche, and C. Béroud, L'analyse des mutations du g??ne p53 dans les cancers humains : le lien entre l'??pid??miologie et la carcinogen??se., m??decine/sciences, vol.16, issue.12, pp.1387-96, 2000.
DOI : 10.4267/10608/1594

M. Lo-iacono, V. Monica, L. Righi, F. Grosso, R. Libener et al., Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study, Journal of Thoracic Oncology, vol.10, issue.3, pp.492-501
DOI : 10.1097/JTO.0000000000000436

W. Mccluggage, R. Soslow, and C. Gilks, Patterns of p53 immunoreactivity in endometrial carcinomas: ???all or nothing??? staining is of importance, Histopathology, vol.23, issue.4, pp.786-794, 2011.
DOI : 10.1111/j.1365-2559.2011.03907.x

P. Kaye, S. Haider, P. James, I. Soomro, J. Catton et al., Novel staining pattern of p53 in Barrett???s dysplasia - the absent pattern, Histopathology, vol.15, issue.Suppl. I, pp.933-938, 2010.
DOI : 10.1111/j.1365-2559.2010.03715.x

D. Hellberg, T. Tot, and U. Stendahl, Pitfalls in immunohistochemical validation of tumor marker expression ??? Exemplified in invasive cancer of the uterine cervix, Gynecologic Oncology, vol.112, issue.1, pp.235-275, 2009.
DOI : 10.1016/j.ygyno.2008.09.013

G. Guo, J. Chmielecki, C. Goparaju, A. Heguy, I. Dolgalev et al., Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res, pp.264-273, 2015.

R. Attanoos, A. Griffin, and A. Gibbs, The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2, Histopathology, vol.3, issue.3, pp.231-239, 2003.
DOI : 10.1046/j.1365-2559.1997.2150833.x

S. Willems, M. Wiweger, J. Van-roggen, and P. Hogendoorn, Running GAGs: myxoid matrix in tumor pathology revisited: What's in it for the pathologist? Virchows Arch, Feb, vol.456, issue.2, pp.181-92, 2010.

E. Mark and D. Shin, Diffuse malignant mesothelioma of the pleura: A clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival, Virchows Archiv A Pathological Anatomy and Histopathology, vol.22, issue.6, pp.445-51, 1993.
DOI : 10.1007/BF01606452

P. Baker, P. Clement, and R. Young, Malignant Peritoneal Mesothelioma in Women, American Journal of Clinical Pathology, vol.123, issue.5, pp.724-761, 2005.
DOI : 10.1309/2H0NVRERPP2LJDUA

L. Chirieac, J. Barletta, B. Yeap, W. Richards, T. Tilleman et al., Clinicopathologic Characteristics of Malignant Mesotheliomas Arising in Patients With a History of Radiation for Hodgkin and Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.31, issue.36, pp.4544-4553, 2013.
DOI : 10.1200/JCO.2013.49.9616

D. Henderson, G. Reid, S. Kao, N. Van-zandwijk, and S. Klebe, Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA, Journal of Clinical Pathology, vol.14, issue.Suppl. 1, pp.854-61, 2013.
DOI : 10.1136/jclinpath-2013-201609

K. Suzuki, K. Kadota, C. Sima, M. Sadelain, V. Rusch et al., Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients, Cancer Immunology, Immunotherapy, vol.137, issue.12, pp.1721-1729, 2011.
DOI : 10.1007/s00262-011-1073-8

H. Ujiie, K. Kadota, J. Nitadori, J. Aerts, K. Woo et al., The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers, OncoImmunology, vol.34, issue.6, p.1009285, 2015.
DOI : 10.1002/(SICI)1097-0258(20000115)19:1%3c113::AID-SIM245%3e3.0.CO;2-O

R. Cornelissen, L. Lievense, A. Maat, R. Hendriks, H. Hoogsteden et al., Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma, PLoS ONE, vol.44, issue.9, p.106742, 2014.
DOI : 10.1371/journal.pone.0106742.t002

C. Combaz-lair, F. Galateau-sallé, A. Mcleer-florin, L. Stang, N. David-boudet et al., Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas, Human Pathology, vol.52, pp.9-18
DOI : 10.1016/j.humpath.2016.01.010

C. Cebulla, E. Binkley, R. Pilarski, J. Massengill, K. Rai et al., Germline Gene Mutation in Young Uveal Melanoma Patients, Ophthalmic Genetics, vol.36, issue.2, pp.126-157
DOI : 10.1002/(SICI)1097-0215(19990730)82:3<325::AID-IJC3>3.0.CO;2-G

A. Wang, A. Papneja, M. Hyrcza, A. Habeeb, and D. Ghazarian, BAP1: gene of the month, J Clin Pathol, 2016.

L. Diaz, A. Okonkwo, E. Solans, C. Bedrossian, and M. Rao, Extensive myxoid change in well-differentiated papillary mesothelioma of the pelvic peritoneum, Annals of Diagnostic Pathology, vol.6, issue.3, pp.164-171, 2002.
DOI : 10.1053/adpa.2002.33902